跳转到内容

来立司琼

维基百科,自由的百科全书
来立司琼
臨床資料
其他名稱F-0930-RS
ATC碼
  • 未分配
识别信息
  • 1-Benzyl-2-piperazin-1-yl-1H-benzimidazole
CAS号143257-98-1  checkY
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C18H20N4
摩尔质量292.39 g·mol−1
  • InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2 checkY
  • Key:PWWDCRQZITYKDV-UHFFFAOYSA-N checkY

来立司琼INN:lerisetron;开发代号:F-0930-RS)是一种用作5-HT3受体拮抗剂的药物。[1]它是一种有效的止吐剂[2][3]目前正在临床试验中用于治疗与癌症化疗相关的恶心。[4]

参考资料

[编辑]
  1. ^ Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. Journal of Medicinal Chemistry. February 1997, 40 (4): 586–93. PMID 9046349. doi:10.1021/jm960442e. 
  2. ^ Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. Acta Oncologica. 1998, 37 (7–8): 759–63. PMID 10050999. doi:10.1080/028418698430160. 
  3. ^ Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. Arzneimittel-Forschung. 2002, 52 (9): 689–94. PMID 12404884. S2CID 24423582. doi:10.1055/s-0031-1299952. 
  4. ^ Huckle R. Lerisetron. FAES. Current Opinion in Investigational Drugs. July 2003, 4 (7): 874–7. PMID 14619411.